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Previewsin future prospective clinical trials in which
cancer patientswill receive targeted thera-
pies based on these profiles. This is a very
important application inmodern oncology.
Besides, novel chemotherapy drugs (e.g.,
antibodies or small inhibitors) that target
specific receptors or molecular pathways
on cancer cells have been developed
over the past ten years (Wan et al., 2013).
Although these drugs are administered to
target metastatic cells, current stratifica-
tion of therapy is based largely on the anal-
ysis of the resected primary tumor. How-
ever, metastases occur in many patients
years after primary tumor diagnosis, and
they can harbor unique genomic alter-
ations different from the bulk of the original
primary tumor cells (Kang and Pantel,
2013). Thus, thedirect analysisofmetasta-
tic cells will reveal important information
for a systemic cancer therapy targeting
metastatic disease. However, a biopsy of
overt metastases is an invasive procedure
limited to certain locations and not easily
acceptable in the clinic. Moreover, recent
work has shown that different metastatic
sites harbor different genomic aberrations,
and biopsies of one or two accessible me-
tastases may not be representative. Thus,
the assessment of the TEP mRNA profile
might provide real-time information on
the actual status of metastatic lesions. In
this regard, future comparative studies
will show whether the TEP approach is su-554 Cancer Cell 28, November 9, 2015 ª201perior or complementary to othermeansof
liquidbiopsy (e.g., ctDNAorCTCanalyses)
in stratifying individual patients to the
appropriate therapy.
Before these clinical trials can be con-
ducted, the robustness of the assay and
factors confounding the blood platelet
mRNA profile need to be investigated.
The authors recommend isolation of the
platelet fraction within 48 hr after blood
withdrawal; however, research on many
cell types has indicated that mRNA pro-
files will change during this time period.
In addition, systemic factors such as
chronic or transient inflammatory dis-
eases or cardiovascular events and other
non-cancerous diseases may also influ-
ence the platelet mRNA profile.
Taken together, the ability of TEPs to
pinpoint the location of the primary tumor
might advance the use of liquid biopsies
for cancer diagnostics. Further validation
is warranted to determine the clinical utility
of TEP profiles for blood-based liquid bi-
opsy. The validationof liquidbiopsyassays
is an important task of the new European
consortium CANCER-ID that comprises
more than 30 institutions from academia
and industry (http://www.cancer-id.eu).ACKNOWLEDGMENTS
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Metastasis to distant organs depends on pathological crosstalk between tumor cells and various tissue-spe-
cific stromal components. Zhang and colleagues recently demonstrated that astrocyte-derived exosomal
miR-19a reversibly downregulated PTEN expression in cancer cells, thereby increasing their CCL2 secretion
and recruitment of myeloid cell to promote brain metastasis.Stephen Paget’s visionary ‘‘seed and soil’’
hypothesis underscored the importance
ofmutual compatibility between tumor cellsand host organs in the formation of
metastatic lesions. Such compatibility may
stem from the intrinsic characteristics ofcancer cells and the host microenvi-
ronments, but could also be developed











Figure 1. Exosome-Mediated Tumor-Stromal Crosstalk Primes the Outgrowth of Brain
Metastases
After dissemination to the brain, metastatic cancer cells may release factors to recruit astrocytes and
induce astrogliosis. Astrocytes secrete miR-19a-containing exosomes into the brain microenvironment
that can be taken up by cancer cells, leading to reduced PTEN levels and subsequent increased NFkB-
dependent production of CCL2. Tumor-derived CCL2 recruits IBA1+ myeloid cells to stimulate prolifer-
ation and inhibit apoptosis of brain-metastatic cancer cells. It is possible that additional intercellular
interactions and stromal components not depicted in this diagram are involved in the tumor-promoting
function of reactive astrocytes.
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Previewsmetastatic outgrowth. Specifically, meta-
static cancers can effect alterations in
distant sites by long-distance communica-
tion through secreted factors, fostering
the formation of pre-metastatic niches.
More extensive molecular crosstalk occurs
locally between tumor cells and stromal
cells at the site of metastasis, often through
self-amplifying positive feedback loops, or
‘‘vicious cycles’’. Bone metastasis is one
of the most extensively studied examples
of such tumor-stromal interactions in or-
gan-tropic metastasis, where intricate mo-
lecular interactions between tumor cells,
residential bone cells, and the bone matrix
drive the formation of osteolytic or osteo-
blastic lesions (Weilbaecher et al., 2011).
The study of organ-tropic metastasis to
the brain has also been quickly gainingmo-
mentum. Several recent studies have iden-
tified a number of brain-derived factors,
including secreted proteins and microRNA
(miRNA)-containing exosomes that alter
the brain microenvironment to promote
the survival and outgrowth of brain metas-
tasis (Fong et al., 2015; Sevenich et al.,
2014; Valiente et al., 2014). However, the
flip side of the ‘‘seed and soil’’ paradigm,
i.e., how brain stroma provides an intrinsi-
cally compatible environment for metas-
tasis formation, remainspoorlyunderstood.
Astrocytes are a major stromal cell type
in the brain. Reactive astrocytes, a com-mon pathological response during the
repair and scarring of the brain following
injury, are often associated with brain
metastases in animal models and human
patients (Kodack et al., 2015). Reactive
astrocytes have been shown to enhance
tumor cell proliferation, survival, invasive
capabilities, and resistance to chemo-
therapy (Kodack et al., 2015), although
the mechanistic insight into such metas-
tasis-promoting effects of astrocytes re-
mains limited. In a recent issue of Nature,
Zhang et al. (2015) unveiled a complex
reciprocal communication betweenmeta-
static tumor cells, astrocytes, and other
brain stromal cells that primes the suc-
cessful outgrowth of overt brain metasta-
ses (Figure 1).
When analyzing gene expression pro-
files of clinical and experimental metasta-
ses of breast cancer to various organs,
the authors noticed a marked downregu-
lation of PTEN mRNA specifically in brain
metastases compared to primary and
other secondary tumors. Furthermore,
analysis of PTEN protein levels confirmed
a significantly higher rate of PTEN loss in
brain metastases than primary breast tu-
mors. Because genetic manipulation of
PTEN expression in tumor cells did not
affect their in vivo brain metastatic ability
and PTEN-low brain metastases regained
PTEN expression upon cell culture, theCancer Cell 28,authors hypothesized that a reversible
loss in PTENwas imposed on cancer cells
by the brain microenvironment.
Co-culture experiments identified astro-
cytes as the cell type responsible for the
reversible PTEN downregulation during
brain metastasis. Specifically, miR-19a
emerged among a number of known
PTEN-targeting miRNAs as the mediator
of PTEN suppression through intercellular
transfer of miR-19a from astrocytes to
tumor cells via exosomes. Treatment with
astrocyte-derived exosomes led to a
dose-dependent increase in miR-19a and
a subsequent decrease of PTENmRNA in
cancer cells. Conversely, conditioned me-
dia from astrocytes treated with either
an inhibitor or siRNA targeting Rab27a
to block secretion of exosomes failed to
reduce the PTEN level in tumor cells.
Mimicking the therapeutic setting, intracra-
nial injection of Rab27a/b shRNA lentivi-
ruses blocked exosome secretion in the
brainparenchyma,preventedPTENdown-
regulation in tumors, and significantly
decreased metastatic outgrowth, which
could be rescued by co-injection with
astrocyte-derived exosomes.
To understand how PTEN reduction
supports brain metastatic outgrowth, the
authors conditionally manipulated PTEN
levels in tumor cells and discovered that
PTEN loss promoted metastasis only
after tumor cell extravasation, while PTEN
restoration suppressed tumor growth.
Moreover, PTEN restoration led toa reduc-
tion in CCL2 secretion due to the inhibition
of the NF-kB pathway, whereas PTEN
knockdown increased signaling through
thispathway toenhanceCCL2expression.
CCL2 attracts IBA1+ myeloid cells to the
brain metastatic tumors to promote tumor
growthby increasingproliferation and sup-
pressing apoptosis of cancer cells. Impor-
tantly, Zhang et al. (2015) demonstrated
that human breast cancer brain metasta-
ses had higher levels of CCL2 than did
primary tumors and that the low PTEN
expression in brain metastases correlated
with an increased CCL2 level and IBA1+
myeloid cell number. These findings sug-
gested that the proposed mechanism of
tumor-astrocyte interaction also occurs in
clinical brain metastasis.
While exosomes have attracted much
interest as cancer-secreted mediators
of metastatic niche formation due to
their ability to mediate long-distance tu-
mor-stroma communications (Costa-SilvaNovember 9, 2015 ª2015 Elsevier Inc. 555
Cancer Cell
Previewset al., 2015; Fong et al., 2015; Peinado
et al., 2012), the role of stromal exosomes
has not been extensively investigated.
Transfer of miRNA from host stroma to
cancer cells has previously been reported
in bone metastasis where dormancy-
inducing miRNAs are transported from
bone marrow stromal cells, such as
mesenchymal stem cells, to breast cancer
cells through gap-junctions and exo-
somes, allowing the tumor cells to survive
high-dose chemotherapy (Lim et al.,
2011;Onoetal., 2014). The studybyZhang
et al. (2015) represents one of the first
reported scenarios in which brain stroma
actively secretesexosomes toaffect tumor
cell behavior. Considering the significant
diagnostic and prognostic potential of
using circulating exosomes for non-
invasive liquid biopsy analysis, evidence
linking astrocyte-derived exosomes and
their specific molecular contents (e.g.,
miR-19a) with emerging brain metastases
is needed to validate their utility for early
detection of brain metastasis. Because
reactive astrocytes have been proposed
as a sensitive biomarker to enable sub-
stantiallyearlierdetectionofbrainmetasta-
ses thancurrent clinical approaches,circu-
lating exosomes reflecting the presence of
tumor-associated astrogliosis might com-
plement such an imaging approach to
increase the sensitivity and specificity of
brain metastasis risk assessment. More-
over, a potential therapeutic application in
treating or preventing brain metastasis by
inhibiting exosomal transfer of astrocyte
miR-19a or by blocking CCL2 signaling re-
quires further pre-clinical evaluation.
Considering the importance of the
viscous cycle in osteolytic bone metas-556 Cancer Cell 28, November 9, 2015 ª201tasis in which tumor-derived factors drive
osteoclast activation and bone destruc-
tion, releasing bone-embedded factors
to further enhance tumor malignancy
(Weilbaecher et al., 2011), it is compel-
ling to speculate that an analogous pos-
itive feedback loop is also operating in
brain metastasis. Indeed, it has been
shown that gliosis can be induced by
metastatic breast cancer (Kodack et al.,
2015). A possible ‘‘vicious cycle’’ sce-
nario in brain metastasis may be initiated
by tumor-promoted gliosis, either as part
of a brain pre-metastatic niche through
long-distance tumor-derived factors or
through local interactions upon arrival of
tumor cells in the brain. Subsequently,
reactive astrocytes may elevate produc-
tion of metastasis-promoting factors,
including miR-19a-containing exosomes,
which feed back to cancer cells to post-
transcriptionally reduce PTEN levels and
promote metastatic outgrowth through
myeloid cell recruitment (Figure 1). How-
ever, it is currently not well understood
how metastatic cancer cells induce glio-
sis or whether production of exosomes
by astrocytes is influenced by cancer
cells. Hence, it would be interesting to
examine how juxtacrine or paracrine
signaling from cancer cells or cancer-
derived factors may result in qualitative
and quantitative changes of the secre-
tome and exosomes released by reactive
astrocytes. It should also be expected
that the downregulation of PTEN in
breast cancer cells by transfer of exoso-
mal miR-19a, as shown by Zhang et al.
(2015), may represent just one of many
mechanisms by which astrocytes and
other brain stromal cells promote brain5 Elsevier Inc.metastasis. Further research in this di-
rection will likely yield additional novel
insights and facilitate the development
of new therapeutic approaches to thwart
the formation of brain metastasis.REFERENCES
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